INRLF (Valneva SE) Stock Based Compensation: $0.0 Mil (TTM As of Mar. 2026)


INRLF Valneva SE INRLF
55 GF Score
Price $2.62
GF Value $2.69
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE Stock Based Compensation?

Valneva SE INRLF 55 Stock Based Compensation is $0.0 Mil as of Mar. 2026. GuruFocus rates INRLF with a GF Score™ of 55/100 and a GF Value™ of $2.69 (Fairly Valued). The stock has 6 warning signs investors should review.

Valneva SE's Stock Based Compensation for the three months ended in Mar. 2026 was $0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.0 Mil.

Valneva SE Stock Based Compensation Related Terms

Valneva SE Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Valneva SE's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE Stock Based Compensation Chart

Valneva SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.39 -9.17 5.57 8.35 11.16

Valneva SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INRLF
55GF Score
Valneva SE INRLF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valneva SE Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Stock Based Compensation of $0.0 Mil mean?
Valneva SE (INRLF) has a Stock Based Compensation of $0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Valneva SE and its competitors.
Is Valneva SE's Stock Based Compensation too high?
Valneva SE's current Stock Based Compensation is $0.0 Mil. Overall, Valneva SE has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Stock Based Compensation compare to VRTX and REGN?
Valneva SE's Stock Based Compensation of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Valneva SE and its competitors. Valneva SE's current Stock Based Compensation is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.69, compared to a current price of $2.62 — trading 2.6% below its estimated fair value. The current Stock Based Compensation is $0.0 Mil. Valneva SE's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Valneva SE (INRLF), the current Stock Based Compensation is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 2.6% below its estimated GF Value™ of $2.69. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • Stock Based Compensation: $0.0 Mil
  • GF Value™: $2.69 vs. price of $2.62 (2.6% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
55GF Score

Get the complete analysis for INRLF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.69
GF Value